{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T16:06:56Z","timestamp":1761581216996,"version":"build-2065373602"},"reference-count":20,"publisher":"Elsevier BV","issue":"14","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Princess Margaret Prostate Cancer Research Program (PMH Foundation)"},{"name":"Prostate Cancer Canada (AMJ)"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1016\/j.ejca.2014.06.004","type":"journal-article","created":{"date-parts":[[2014,7,16]],"date-time":"2014-07-16T08:34:00Z","timestamp":1405499640000},"page":"2399-2407","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Abiraterone acetate in metastatic castration-resistant prostate cancer: A retrospective review of the Princess Margaret experience of (I) low dose abiraterone and (II) prior ketoconazole"],"prefix":"10.1016","volume":"50","clinical-trial-number":[{"clinical-trial-number":"nct01543776","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Raya","family":"Leibowitz-Amit","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jo-An","family":"Seah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eshetu G.","family":"Atenafu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnoud J.","family":"Templeton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco E.","family":"Vera-Badillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nimira","family":"Alimohamed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer J.","family":"Knox","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian F.","family":"Tannock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Srikala S.","family":"Sridhar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony M.","family":"Joshua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"21","key":"10.1016\/j.ejca.2014.06.004_b0005","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"de Bono","year":"2011","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ejca.2014.06.004_b0010","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1209096","article-title":"Abiraterone in metastatic prostate cancer without previous chemotherapy","volume":"368","author":"Ryan","year":"2013","journal-title":"N Engl J Med"},{"issue":"28","key":"10.1016\/j.ejca.2014.06.004_b0015","doi-asserted-by":"crossref","first-page":"4563","DOI":"10.1200\/JCO.2007.15.9749","article-title":"Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven","volume":"26","author":"Attard","year":"2008","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.ejca.2014.06.004_b0020","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1200\/JCO.2009.24.1281","article-title":"Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy","volume":"28","author":"Ryan","year":"2010","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.ejca.2014.06.004_b0025","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/ncpuro1237","article-title":"CYP17 inhibition as a hormonal strategy for prostate cancer","volume":"5","author":"Reid","year":"2008","journal-title":"Nat Clin Pract Urol"},{"issue":"4","key":"10.1016\/j.ejca.2014.06.004_b0030","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1002\/pros.21447","article-title":"Contemporary experience with ketoconazole in patients with metastatic castration-resistant prostate cancer: clinical factors associated with PSA response and disease progression","volume":"72","author":"Keizman","year":"2012","journal-title":"Prostate"},{"issue":"9","key":"10.1016\/j.ejca.2014.06.004_b0035","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1200\/JCO.2009.25.9259","article-title":"Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer","volume":"28","author":"Danila","year":"2010","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2014.06.004_b0040","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.ijrobp.2006.04.029","article-title":"Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference","volume":"65","author":"Roach","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.ejca.2014.06.004_b0045","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.eururo.2013.11.002","article-title":"EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer","volume":"65","author":"Heidenreich","year":"2014","journal-title":"Eur Urol"},{"issue":"7","key":"10.1016\/j.ejca.2014.06.004_b0050","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","article-title":"Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group","volume":"26","author":"Scher","year":"2008","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2014.06.004_b0055","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1093\/annonc\/mdt581","article-title":"Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer.","volume":"5","author":"Leibowitz-Amit","year":"2014","journal-title":"Ann Oncol"},{"issue":"15_suppl","key":"10.1016\/j.ejca.2014.06.004_b0060","first-page":"5013","article-title":"A prognostic model for predicting overall survival (OS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA) after docetaxel","volume":"31","author":"Chi","year":"2013","journal-title":"ASCO Meeting Abst"},{"issue":"26","key":"10.1016\/j.ejca.2014.06.004_b0065","doi-asserted-by":"crossref","first-page":"3298","DOI":"10.1200\/JCO.2013.51.5023","article-title":"Evaluation of treatment benefit: randomized controlled trials and population-based observational research","volume":"31","author":"Booth","year":"2013","journal-title":"J Clin Oncol"},{"issue":"Supplement","key":"10.1016\/j.ejca.2014.06.004_b0070","article-title":"Evaluation of continuous abiraterone acetate (AA) plus prednisone (P) dosing in fasting and fed states in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)","author":"Chi","year":"2013","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.ejca.2014.06.004_b0075","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3111\/13696998.2013.877020","article-title":"An incidence model of the cost of advanced prostate cancer in Spain","volume":"17","author":"Hart","year":"2014","journal-title":"J Med Econ"},{"issue":"16","key":"10.1016\/j.ejca.2014.06.004_b0080","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1056\/NEJMp1400104","article-title":"Comparative effectiveness questions in oncology","volume":"370","author":"Mailankody","year":"2014","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ejca.2014.06.004_b0085","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.coph.2008.06.004","article-title":"Targeting CYP17: established and novel approaches in prostate cancer","volume":"8","author":"Yap","year":"2008","journal-title":"Curr Opin Pharmacol"},{"issue":"17","key":"10.1016\/j.ejca.2014.06.004_b0090","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.1021\/jm950749y","article-title":"3- and 4-pyridylalkyl adamantanecarboxylates: inhibitors of human cytochrome P450(17 alpha) (17 alpha-hydroxylase\/C17,20-lyase). Potential nonsteroidal agents for the treatment of prostatic cancer","volume":"39","author":"Chan","year":"1996","journal-title":"J Med Chem"},{"issue":"6","key":"10.1016\/j.ejca.2014.06.004_b0095","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1200\/JCO.2004.06.037","article-title":"Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583)","volume":"22","author":"Small","year":"2004","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2014.06.004_b0100","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1200\/JCO.2003.06.100","article-title":"Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer","volume":"21","author":"Halabi","year":"2003","journal-title":"J Clin Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804914007485?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804914007485?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:21:14Z","timestamp":1760732474000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804914007485"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":20,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["S0959804914007485"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2014.06.004","relation":{},"ISSN":["0959-8049"],"issn-type":[{"type":"print","value":"0959-8049"}],"subject":[],"published":{"date-parts":[[2014,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Abiraterone acetate in metastatic castration-resistant prostate cancer: A retrospective review of the Princess Margaret experience of (I) low dose abiraterone and (II) prior ketoconazole","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2014.06.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}